Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Tuesday

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Atara Biotherapeutics to post earnings of ($3.77) per share for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to analysts' expectations of $48.30 million. On average, analysts expect Atara Biotherapeutics to post $-12 EPS for the current fiscal year and $-17 EPS for the next fiscal year.

Atara Biotherapeutics Stock Down 2.6 %

NASDAQ ATRA traded down $0.27 during trading hours on Wednesday, hitting $10.01. The company's stock had a trading volume of 157,899 shares, compared to its average volume of 105,461. The stock has a fifty day moving average of $8.41 and a 200 day moving average of $10.51. The firm has a market capitalization of $49.20 million, a P/E ratio of -0.26 and a beta of 0.50. Atara Biotherapeutics has a twelve month low of $4.96 and a twelve month high of $39.50.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Canaccord Genuity Group restated a "buy" rating and issued a $13.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. The Goldman Sachs Group decreased their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a "sell" rating on the stock in a research report on Wednesday, July 17th. HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Mizuho upgraded Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and cut their target price for the company from $25.00 to $18.00 in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $14.00.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.